Raut Serums India Pvt Ltd Honoured with India Pharma Award 2025

Raut Serums India Pvt. Ltd. has been honoured with the India Pharma Award 2025 for its innovative Snake Bite Venom Detection Kit. The award was received by Dr. Anil Yadav on behalf of the Raut Serums Ind Pvt. Ltd. at a ceremony held in Delhi. This recognition highlights Raut Serums commitment to developing life-saving solutions that strengthen emergency and rural healthcare systems.

India Creates Global History in Snakebite Management

Development of the World’s First Rapid Snake Venom Detection Kit (SVDK)

India has achieved an unprecedented milestone in the field of snakebite management and  public health by successfully developing the world’s first Rapid Snake Venom Detection Kit (SVDK). This landmark innovation represents a historic breakthrough not only for India but also for global healthcare systems addressing snakebite envenomation.

This pioneering achievement has been jointly realized by the following three Indian companies, who together have made a transformative contribution to healthcare innovation:

• Raut Serums India Pvt. Ltd. (RSIPL), Pune
• Biorad Medisys Pvt. Ltd., Pune
• Bhat Biotech Ltd., Bengaluru

Public Health Need and Social Impact

Snakebite envenomation remains a major public health challenge, particularly in rural, tribal, and remote regions, where delayed diagnosis and inappropriate treatment result in significant morbidity and mortality.

In snakebite cases, every minute is critical. A rapid and accurate determination of whether venom has been injected is essential for making correct clinical decisions. Until now, the absence of such diagnostic capability often led to:

• Unnecessary panic and delays in treatment
• Empirical and excessive use of Anti-Snake Venom (ASV)
• Increased risk of adverse reactions, including anaphylaxis
• Avoidable financial burden on economically weaker patients

The SVDK addresses this critical gap by providing rapid, reliable, and precise detection of snake venom within minutes, enabling clinicians to determine:

• Whether venom is present
• Whether ASV administration is required

This ensures timely, evidence-based, and safe clinical intervention, while preventing unnecessary or excessive use of antivenom.

For rural farmers, tribal communities, and economically disadvantaged families, the SVDK functions as a true life-saving intervention.

Technical Leadership and Key Contributors

This globally significant innovation was achieved through exceptional scientific leadership, technical expertise, and collaborative effort:

Technical Leadership & Scientific Guidance

• Dr. Anil Yadav
• Technical Director, Raut Serums India Pvt. Ltd., Pune
• Dr. Vivek Wayse
• Technical Director & Patent Holder, Biorad Medisys Pvt. Ltd., Pune
• RSIPL & Biorad Medisys Scientific and Technical Teams
• Development Under guidance by Mr. Natha Raut
• CMD, Raut Serums India Pvt. Ltd., Pune

Patent Holder:

• Dr. Vivek Wayse
• Mr. Pradeep Divate
• Adv. Vishal Kataria
• Dr. Jitendra Hegde
• CMD, Biorad Medisys Pvt. Ltd., Pune

Manufacturing site At.

• Bhat Biotech Ltd., Bengaluru
• CMD: Dr. Sama Bhatt

National & International Recognition

The global importance and innovation value of the SVDK were formally recognized at the CPHI & PMEC Pharma Awards 2025, held in New Delhi on 25 November 2025.

Award Received:

Pharma Innovation of the Year – Product (Pharma Award 2025)

By winning this prestigious international award, the three collaborating companies have demonstrated India’s leadership in healthcare innovation and translational research on a global platform.

Government of Maharashtra – Public Health Adoption

Recognizing the clinical value, public health relevance, and social impact of the SVDK, the Government of Maharashtra has taken a landmark policy decision.

With the approval of:

• Hon’ble Chief Minister Shri Devendra Fadnavis ji
• Hon’ble Deputy Chief Minister Shri Ajit Pawar ji
• Hon’ble Deputy Chief Minister Shri Eknath Shinde ji
• Hon’ble Health Minister Shri Prakash Abitkar ji
• The state government has approved the procurement of 1,10,213 SVDK kits.

These kits will be distributed free of cost across: Maharashtra

• Government hospitals
• District hospitals
• Primary Health Centres (PHCs)

This initiative is expected to save thousands of lives by ensuring early, accurate diagnosis and rational treatment of snakebite cases throughout Maharashtra.

Alignment with National & Global Health Policies

The SVDK is fully aligned with international and national public health strategies, including:

• WHO / CDSCO Snakebite Strategy 2030
• Target: 50% reduction in snakebite-related mortality and disability
• NCDC, Government of India – National Snakebite Prevention and Control Programme

Core Objectives of the Innovation

The fundamental goals of the SVDK initiative are:

• Saving human lives
• Reducing treatment costs for economically weaker sections
• Enabling rapid and accurate clinical decision-making
• Ensuring safe, rational, and evidence-based use of anti-venom

Global Significance

Through the development of the SVDK, India has not merely created a diagnostic innovation—India has saved lives.

This achievement stands as a source of national pride and marks a new milestone in Indian biomedical research, diagnostics, and public healthcare delivery.